Fund shareholders of SENSEI BIOTHERAPEUTICS INC
ISIN US81728A2078 · United States · LEI 8945002MP2CXKAENWU30
- Fund shareholders
- 9
- Of which ETFs
- 1 8 other funds
- Value held
- 5.4M $
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 180,711 | 4.9M $ | 0.43 % | as of Jul 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 10,115 | 252.9K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 4,576 | 96.7K $ | 0.00 % | as of May 31, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 3,192 | 79.8K $ | 0.01 % | as of Jun 30, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 1,416 | 29.9K $ | as of May 31, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 1,253 | 26.5K $ | as of May 31, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 578 | 12.2K $ | as of May 31, 2026 ↗ | |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 210 | 5.3K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 41 | 1K $ | 0.00 % | as of Jun 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.43 % | as of Jul 31, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.01 % | as of Jun 30, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 0.00 % | as of Jun 30, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 0.00 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 9 | +1 | 202,092 | +200.6 % |
| 2026Q2 | 8 | +1 | 67,236 | +310.4 % |
| 2026Q1 | 7 | +2 | 16,382 | +8.3 % |
| 2025Q4 | 5 | +3 | 15,131 | -48.0 % |
| 2025Q3 | 2 | 29,090 |
Institutional managers
28 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Vivo Capital, LLC | 722,020 | 22.8M $ | as of Mar 31, 2026 |
| Cormorant Asset Management, LP | 306,222 | 9.7M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 146,565 | 4.6M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 133,506 | 4.2M $ | as of Mar 31, 2026 |
| STEMPOINT CAPITAL LP | 132,873 | 4.2M $ | as of Mar 31, 2026 |
| Caligan Partners LP | 126,002 | 4M $ | as of Mar 31, 2026 |
| Trails Edge Capital Partners, LP | 125,000 | 3.9M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 65,730 | 2.1M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 61,568 | 1.9M $ | as of Mar 31, 2026 |
| HRT FINANCIAL LP | 58,001 | 1.8K $ | as of Mar 31, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 34,549 | 1.1M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 33,025 | 1M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 32,041 | 1M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 30,000 | 945.6K $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 26,124 | 823.4K $ | as of Mar 31, 2026 |
| Brevan Howard Capital Management LP | 20,333 | 640.9K $ | as of Mar 31, 2026 |
| FRED ALGER MANAGEMENT, LLC | 18,337 | 578K $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 16,205 | 510.8K $ | as of Mar 31, 2026 |
| Catalio Capital Management, LP | 14,718 | 463.9K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 9,501 | 299.5K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 8,872 | 279.6K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 8,795 | 277.2K $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 6,351 | 200.2K $ | as of Mar 31, 2026 |
| UBS Group AG | 4,529 | 142.8K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 1,496 | 47.2K $ | as of Mar 31, 2026 |
Declared shareholders of SENSEI BIOTHERAPEUTICS INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Khosla Ventures VI, LP and 5 others | 10.20 % | 2,632,232 | as of Jun 15, 2026 · SCHEDULE 13G |
| Caligan Partners LP and 1 other | 2.40 % | 629,467 | as of Jun 30, 2026 · SCHEDULE 13G |
| Trails Edge Capital Partners, LP and 2 others | 2.00 % | 515,335 | as of Jun 30, 2026 · SCHEDULE 13G |
| StemPoint Capital LP and 2 others | 0.00 % | 0 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of SENSEI BIOTHERAPEUTICS INC". https://titelia.com/en/stocks/sensei-biotherapeutics-inc-US81728A2078